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Abstract
Myeloma is characterized by monoclonal bone marrow plasmacytosis, the presence of M-protein
in serum and/or in urine and osteolytic bone lesions. HIV-seropositive subjects with myeloma are
younger at the time of diagnosis of the tumour and usually the myeloma has a more aggressive
clinical course than it does in HIV-seronegative subjects.
A case of an HIV-seropositive woman in whom myeloma was diagnosed following progressive
swelling of the face, is reported. In addition to bone marrow plasmacytosis and the presence of M-
protein in the serum, the patient had an extramedullary lesion affecting the oral cavity, maxilla,
parotid gland and paranasal sinuses, and extending intracranially and intraorbitally.
Background
Myeloma is an incurable haematological malignancy, the
characteristic cell type of which is terminally differenti-
ated B-lymphocytes. The affected cells accumulate in the
bone marrow, and myeloma accounts for about 10% of
all haematological cancers. Myeloma affects both the
immune and skeletal systems and the tumour cells have
cytogenetic alterations in the variable regions of immu-
noglobulin (Ig) heavy and light chain genes. These
cytogenic abnormalities may mediate the uncontrolled
proliferation, prevent the differentiation, and contribute
to the prolonged survival of myeloma cells [1,2].
Only 5% of subjects with myeloma go into remission after
treatment and the median survival time is about 3 years.
The incidence of myeloma increases with age and the
median age at diagnosis is 68. Males are affected more fre-
quently than females and black persons are affected twice
as frequently as whites. In the late stages of myeloma dis-
ease, increasing numbers of plasma cells may be detected
in the circulating blood and skeletal extramedullary mye-
loma tumours may develop with increasing frequency [1-
4].
The uncontrolled proliferation of myeloma cells is accom-
panied by an increase in their production of monoclonal
Ig proteins (M-protein). The presence of M-protein in
serum or urine can be detected by electrophoresis, and
immunoelectrophoresis or immunofixation is used to
identify the specific heavy (M, G, A, D, E) and light (κ or
λ) Ig chain class [3].
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dence for the diagnosis of myeloma: evidence of M-pro-
tein in the serum or urine (usually ≥ 30 g/L); at least 10%
plasma cells on a myelogram; demonstration of mono-
clonal plasma cells on bone marrow biopsy; and end-
organ damage that may be hypercalcaemia, renal insuffi-
ciency, anemia, osteolytic bone lesions or extramedullary
dissemination of myeloma tumour cells [3,5].
Over 90% of subjects with myeloma have M-protein in
the serum or in the urine at the time of diagnosis, about
60% of them ≥ 30 g/L. Monoclonal plasma cells usually
account for ≥ 10% of all bone marrow nucleated cells, but
may range from ≤ 5% to almost 100% [5,6]. At the time
of diagnosis, subjects with myeloma may present with
hypercalcaemia (15–20% of subjects); with renal insuffi-
ciency measured as serum creatin > 173 mmol/l (about
20%); normocytic normochromic anemia (about 60%);
and bone lesions or pathological fractures of bone (about
80%) [5]. The occurrence of extramedullary dissemina-
tion of myeloma tumour cells at the time of diagnosis is
uncommon.
Solitary plasmacytoma (SP) is a localized variant of mye-
loma presenting either as solitary bone plasmacytoma
(SBP), or as extraskeletal soft tissues when it is termed
extramedullary plasmacytoma (EMP) [7,8].
SP is less common than myeloma and affects younger
subjects who have a median survival of 10 years or more
[2]. The diagnosis of SP is based on histological demon-
stration of monoclonal proliferation of plasma cells with-
out evidence of end-organ damage. Generally subjects
with SP do not have M-protein in the serum or in the
urine, and do not have monoclonal plasmacytosis of
bone marrow [9].
SBP is more common in males than in females, most com-
monly affects the axial skeleton, and the onset is about 10
years earlier than myeloma. In SBP there is sometimes evi-
dence of M-protein < 20 g/L in the serum and/or in the
urine, and monoclonal plasmacytosis of the bone marrow
of < 5% [9-11]. About 50% of subjects with SBP will
develop overt myeloma some 2–3 years after treatment of
their SBP [5,12,13].
In contrast to SBP, EMP most frequently involves the sub-
mucosal lymphoid tissue of the paranasal sinuses,
nasopharynx or the tonsils; [3,11,14] EMP is less common
than SBP and occurs in slightly older subjects [13]. About
15% of subjects with EMP progress to myeloma following
treatment, but the rest are cured [12]. The prognosis of
EMP is therefore substantially different to that of SBP and
of myeloma, suggesting some difference in the pathogenic
mechanisms of the 3 diseases [8].
Myeloma needs to be differentiated from other mono-
clonal gammopathies including heavy chain disease,
monoclonal gammopathy of undetermined significance,
Waldenström macroglobulinemia, SP, plasma cell leuke-
mia and plasmablastic lymphoma [3].
Case presentation
A 48 year-old black female presented at the Medunsa Oral
Health Center with a large swelling of the left side of her
face, and proptosis of her left eye (figure 1). The facial
mass was firm and immobile. The nasolabial furrow was
obliterated by the swelling, the nose was displaced to the
right and the tumour was fungating from the left nostril.
Intraorally, there was a large soft tissue mass growing from
the maxilla, and extending from the left side across the
midline. A large portion of this mass was necrotic (figure
2). The patient stated that the facial swelling had rapidly
enlarged over the previous month, and that she had
recently lost the sight of her left eye. Because of language
and cultural difficulties in communication, we could not
determine why she had not received medical attention
before our consultation.
Microscopic examination of a biopsy specimen from the
intraoral mass showed a neoplastic plasma cell tumour.
The densely packed tumour cells were mainly plasmab-
lasts with prominent nucleoli (figure 3). Aspiration of
Extramedullary myeloma of the head and faceFigure 1
Extramedullary myeloma of the head and face. Note 
the marked distortion of the nose, lips and left eye. 
The tumour affects the left maxillary and zygomatic 
area. There was a midline shift of the nose and the 
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sis (9% of the myelogram) without an increased number
of blasts. The plasma cells were preponderantly mature
with occasional binucleated forms. A trephine biopsy of
bone marrow was not done, so the clonality of the plasma
cell population could not be determined. Erythropoiesis
was reduced.
Serum protein electrophoresis and immunofixation
showed IgG kappa monoclonal protein. Both serum IgG
(35.89 g/L, reference range 7.00 – 16.00) and kappa light
chain (8.4 gr/L, reference range 0.6 – 1.3) were elevated.
The patient was HIV-seropositive with a CD4+ T cell count
of 41 × 10-6/L, and the percentage of CD4 lymphocytes
was 9.06. There was normocytic normochromic anemia,
lymphopenia, and a high platelet count. Serum calcium
and creatin levels were normal. A skeletal survey excluding
the head showed no abnormalities. Ophtalmological
examination confirmed blindness of the patient's left eye.
Computed tomography revealed a large soft tissue mass
measuring 12 cm × 12 cm that had caused destruction of
the left maxillary ethmoid sinus, the sphenoid sinuses and
the left nasal cavity, and extended intra-cranially into the
anterior cranial fossa (figure 4) The intra-orbital tumour
mass caused severe proptosis of the left eye (figure 5). The
mass involved the left nasopharynx, as well as the parotid
and masseteric spaces and the buccal tissues on the left
side. The left submandibular space and the floor of the
mouth were also affected by the tumour (figure 6). The
mandible appeared normal but had been displaced, with-
out evidence of osteolytic or sclerotic lesions. The tumour
mass appeared heterogeneous with hypodense areas of
necrosis (figure 7). Bilateral enlarged cervical lymphnodes
were evident at various levels of the radiographic cuts.
A diagnosis of myeloma was made and the patient was
referred to the regional hospital where she died 5 days
later from respiratory complications.
Note the exophytic, irregular lesions protruding from the palate and fr m the left nost iFigure 2
Note the exophytic, irregular lesions protruding 
from the palate and from the left nostril.
High power photomicrograph of the myelomatous infiltrateFi ure 3
High power photomicrograph of the myelomatous 
infiltrate. Several plasmablasts with prominent 
nucleoli are present (H&E stain, ×400).
Sagittal CT cut showing the extensive destruction of the left maxilla, and the left paranasal tissuesFi ure 4
Sagittal CT cut showing the extensive destruction of 
the left maxilla, and the left paranasal tissues. The 
left orbit is filled with tumorous tissue.Page 3 of 7
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The common denominator to myeloma and SP is the
uncontrolled proliferation of myeloma cells. While mye-
loma is characterized by monoclonal plasmacytosis of the
bone marrow, with or without bone destruction, and by
the presence of M-protein in urine or in serum, in SP there
is no evidence of significant bone marrow plasmacytosis
and less than 30% of subjects with SP have M-protein, and
when it is present it is low compared to the level in mye-
loma [3,7,8].
Our patient met the criteria for a definite diagnosis of
myeloma: her bone marrow plasma cell count was
increased (9% of the myelogram) which approaches the
lower limits for myeloma (10%); the serum protein quan-
tification and immunofixation showed an increased level
of IgG kappa monoclonal protein (M-protein); the pres-
ence of an extramedullary myeloma tumour; and she had
a normocytic normochromic anemia associated with
decrease in bone marrow erythropoiesis.
Since the bone marrow plasma cells were preponderantly
mature forms, and since their clonal nature had not been
established, it is possible that the bone marrow plasmacy-
tosis was reactive to HIV. Even if the bone marrow plas-
macytosis was not associated with the myeloma disease,
the criteria listed in the previous paragraph are sufficient
to establish a diagnosis of myeloma.
Extramedullary dissemination of myeloma usually occurs
several years after the initial diagnosis of myeloma, but
sometimes the extramedullary myeloma can be present at
the time as the diagnosis of myeloma [7]. In the present
case it could not be determined whether the extramedul-
lary mass developed concurrently with the myeloma, sub-
sequently to the primary myeloma or whether this was a
Axial CT cut demonstrating invasion of the tumour into the left orbit, ausing proptosis; a d the extension of the tumour to the left e hmoidal sinus and the temporal and infra- empo-ral f ssaeFigu e 5
Axial CT cut demonstrating invasion of the tumour 
into the left orbit, causing proptosis; and the exten-
sion of the tumour to the left ethmoidal sinus and the 
temporal and infra-temporal fossae.
Axial CT cut showing the invasion of the floor of the mouth by the tumourFigure 6
Axial CT cut showing the invasion of the floor of the 
mouth by the tumour.
Axial CT cut showing the extent of the heterogeneous tumourFigure 7
Axial CT cut showing the extent of the heterogene-
ous tumour.Page 4 of 7
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gressed to a frank myeloma.
EMP in subjects with myeloma is not a rare finding [15].
However, EMP that occurs concurrently with myeloma
should be regarded as extramedullary myeloma (EMM),
and EMP and EMM are two distinct entities with different
prognoses.
Subjects with EMP do not usually have M-protein in
serum and/or in urine, but when present it is only in low
levels; nor do they have bone marrow plasmacytosis and
their skeletal survey is normal. Less than 30% of subjects
with EMP progress to myeloma and 70% of these subjects
survive 10 years [9]. In contrast, EMM is a dissemination
of myeloma cells and should be regarded as end-organ
damage. Subjects with EMM manifest the laboratory char-
acteristics of myeloma, therefore the prognosis of subjects
with EMM is worse than the prognosis of subjects with
EMP, and the management of the two entities differs.
Although, there is a theoretical possibility of concurrence
of EMP with myeloma, this is of academic interest only
because the much more serious myeloma demands prior-
ity.
Early stages of B cell maturation occur in the bone marrow
and are regulated by signals from bone marrow stromal
cells. In the bone marrow, the B cell differentiates up to
the expression of cell surface Ig (s-Ig) receptors. At this
point the B cells exit the bone marrow into the peripheral
circulation and migrate to secondary lymphoid organs,
including lymph nodes, spleen and Peyer's patches of the
gut. In the germinal centers of the peripheral lymph tissue,
further differentiation of B cells is mediated by antigen-
specific interaction with B cell s-Ig that leads to Ig gene
rearrangement and a switch from the expression of IgM to
the expression of IgG or IgA [16]. These activated B cells
(plasmablasts) exit into the bone marrow, stop proliferat-
ing and differentiate into Ig-secreting plasma cells. The
homing of plasma cells into the bone marrow is mediated
by adhesion molecules and interleukins mainly IL-6 [1].
The monoclonal precursors of myeloma cells in the bone
marrow originate in the lymph nodes. The mechanisms
that enable these precursor cells to selectively lodge in the
bone marrow where the particular microenvironment is
conducive to their differentiation, proliferation and sur-
vival are not well understood. However, it is probable that
the bone marrow microenvironment provides the specific
chemotactic signals, and the monoclonal myeloma pre-
cursor cells express the necessary cell surface receptors for
the bone marrow lodgement. There is adhesion to and
transmigrations of the endothelium that lines the bone
marrow sinuses by the monoclonal precursors, which
contribute to the preferential trafficking of these cells in
the bone marrow. The interaction between tumour cells
and the bone marrow stromal cells promotes neoangio-
genesis that is essential for myeloma growth and facilitate
the lodging of new tumour cells in the bone marrow and
their subsequent uncontrolled proliferation. This leads to
the osteolytic activity responsible for the development of
the bone lesions characteristic to myeloma [4,17].
This pathological process is orchestrated by cytokines,
chemokines and growth factors. The neoangiogenesis evi-
dent in the bone marrow of subjects with myeloma is
mediated by increased levels of basic fibroblast growth
factor, vascular endothelial growth factor (VEGF), inter-
leukin (IL)-lβ and tumour necrosis factor (TNF)-α. IL-6 is
an essential growth factor for myeloma cells and pro-
motes their survival. IL-1, VEGF, macrophage inhibitory
factor (MIP) 1α, TNF-α, receptor activator of nuclear fac-
tor-κB (RANK) ligand and osteoprotegerin are agents
mediating the osteoclastic activity that brings about the
myeloma-associated osteolytic bony lesions [1,6,10,18].
Myeloma cells demonstrate cytogenetic abnormalities
that may contribute to their proliferation and prolonged
survival [1]. Myeloma cells do not have significant self-
renewal potential and alone most probably cannot main-
tain the myeloma disease. Myeloma cells, like normal
mature plasma cells express syndecan-1 (CD 138) cell sur-
face antigen that is limited to terminally differentiated
plasma cells originating of B lymphocyte lineage [19]. It is
possible that the cells that maintain the oncogenic growth
of myeloma are originally B lymphocytes which do not
express CD 138. These cells are post-germinal center B
cells, share monoclonal Ig gene sequences with myeloma
cells, and subsequently differentiate into CD138+ mye-
loma cells. These particular B lymphocytes are probably
already transformed and serve as neoplastic progenitor
cells responsible for the perpetuation of myeloma [19].
This concept is supported by the evidence that plasmab-
lastic myeloma with extramedullary involvement has an
immunophenotypic profile and a morphologic pattern
very similar to plasmablastic lymphoma, a post-germinal
center B-cell/plasma cell neoplasm. At times, the differen-
tiation between plasmablastic lymphoma and myeloma
with extramedullary involvement must depend on such
parameters as increased levels of monoclonal Ig mole-
cules and osteolytic bone lesions that are diagnostic for
myeloma [20,21].
This pathogenic background is significant for the treat-
ment of myeloma. Current treatment targets myeloma
cells, and assessment of response to therapy includes
monitoring of the decline in bone marrow plasmacytosis
and the decline in monoclonal Ig levels. Improvement in
these parameters and in the clinical behavior of myelomaPage 5 of 7
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are not eradicated [19].
Myeloma or SP affecting the mouth and the jaws are
uncommon. The mandible is more frequently involved
than the maxilla and the bony lesions of both have a pre-
dilection for the posterior areas of the jaws [22,23]. It is
estimated that in about 30% of subjects with either mye-
loma or with SP, the mouth and jaws may be involved
[23], and oral lesions may be the primary manifestation
[24,25]. The oral symptoms associated with myeloma or
SP include osteolytic bone lesions, jaw pain, paraesthesia,
burning mouth syndrome, amyloidosis of the oral soft tis-
sues, haemorrhage, and an exophytic soft tissue growth
[23-27].
Our patient was not aware of her HIV infection prior to
our examination. Despite the fact that HIV infection is
associated with increased frequencies of B cell lympho-
mas compared to the general population, there are no
reports of a similar increase in the prevalence and inci-
dence of myeloma tumors in relation to HIV infection
[28,29]. However, the frequency of myeloma in HIV-sero-
positive subjects is increased compared to the general
population [30]. Myeloma may be the first indicator lead-
ing to the diagnosis of HIV infection [31]. HIV-seroposi-
tive subjects are diagnosed with myeloma at a younger
age, and have a more aggressive clinical course of their
myeloma disease, compared to HIV-seronegative subjects
[29,30,32,33].
The diagnosis of myeloma in HIV-seropositive subjects
may not be straightforward because HIV infection and
myeloma share some clinical and laboratory features
including recurrent bacterial infections, anaemia, bone
marrow plasmacytosis, polyclonal hypergamma-glob-
ulinemia and monoclonal gammopathy [28-30,34].
The pathogenic mechanisms that are associated with the
increased frequency of myeloma in HIV-seropositive sub-
jects compared to the general population are not well
understood. However, the persistent polyclonal B cell pro-
liferation related to HIV infection may eventually lead to
clonal selection. The increased levels of interleukin 6 asso-
ciated with HIV infection; and the clonal expansion of
plasma cells caused by co-infection with other viruses
(Epstein-Barr virus, human herpes virus-8) observed in
HIV-seropositive subjects, are some possible mechanisms
that are implicated in the evolution of B cell neoplasms
and the development of myeloma in HIV-seropositive
subjects [29,30,35].
Conclusion
We presented a case of myeloma with an extensive
destruction of the maxillofacial region and with intracra-
nial involvement. The clinical picture was extreme and
tragic.
This case report shows that myeloma should raise suspi-
cion of HIV infection, and that myeloma in the setting of
HIV infection can have an unusual aggressive clinical
course.
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